Aluminium Hydroxide

證據等級: L5

預測適應症: 0 個

ALUMINIUM HYDROXIDE: Drug Repurposing Evaluation — Insufficient Data to Generate Prediction

One-Sentence Summary

Aluminium Hydroxide is a well-established antacid and phosphate-binding agent, broadly used for acid-related gastrointestinal disorders and hyperphosphataemia in chronic kidney disease patients. The TxGNN model did not return any repurposing predictions for this drug in the current analysis cycle, likely due to an unresolved DrugBank ID mapping and missing mechanism of action data. No repurposing candidate can be evaluated at this time; this report documents the current data status and required remediation steps.

Quick Overview

Item	Content
Original Indication	Acid-related gastrointestinal disorders (antacid); hyperphosphataemia management in CKD
Predicted New Indication	— (No TxGNN prediction available)
TxGNN Prediction Score	—
Evidence Level	— (No predictions returned)
Malaysia Market Status	✓ Marketed
Number of Registrations	42
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN knowledge graph pipeline returned an empty predicted_indications list for Aluminium Hydroxide. Based on the query log and data gap inventory, three factors likely explain this:

1. Missing DrugBank ID The drugbank_id field is null. TxGNN relies on DrugBank node identifiers to anchor a drug within the knowledge graph and traverse drug–disease edges. Without a valid DrugBank ID, the model cannot score any disease association, and no candidates are ranked.

2. Unresolved Mechanism of Action (Data Gap DG002 — Severity: High) MOA data was not retrieved despite a successful DrugBank query (query log ID 2, result count: 1). This gap prevents mechanistic reasoning and reduces the model’s ability to identify biologically plausible repurposing targets.

3. Missing Package Insert Safety Data (Data Gap DG001 — Severity: Blocking) TFDA/NPRA package insert warnings and contraindications were not obtained. This is classified as Blocking because it prevents the S1 safety pre-screening step; any prediction that passes the prediction stage cannot be safety-filtered without this data.

Until all three issues are resolved and the prediction pipeline is re-run, no repurposing evaluation can proceed.

Malaysia Market Information

Aluminium Hydroxide has 42 active registrations with Malaysia’s NPRA, confirming it is a well-established marketed product. Detailed product-level information (individual product names, dosage forms, manufacturers, and approved indication text) was not included in the current data pull and requires a follow-up targeted query to the NPRA database.

Safety Considerations

Please refer to the package insert for safety information.

Note: No drug–drug interaction data was found (DDI query status: not_found, 0 interactions). This likely reflects the absence of a DrugBank ID linkage rather than a true absence of interactions for Aluminium Hydroxide. Aluminium Hydroxide is known to chelate several oral medications (e.g., fluoroquinolones, tetracyclines, bisphosphonates) and this should be assessed once DrugBank mapping is restored.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model returned no predictions for Aluminium Hydroxide due to a missing DrugBank ID and unresolved data gaps in MOA and safety data; there is currently no repurposing candidate to evaluate, and proceeding without resolving these gaps would yield unreliable results.

To proceed, the following is needed:

Resolve DrugBank ID mapping — Search DrugBank for “aluminium hydroxide” / “aluminum hydroxide” (DB01667 is the expected entry) and link it to the pipeline; this is the single highest-priority action as it unblocks TxGNN graph traversal
Retrieve MOA data (DG002) — Query DrugBank API using the resolved ID to obtain mechanism of action, pharmacology, and drug categories
Download and parse NPRA/TFDA package insert (DG001) — Extract warnings, contraindications, and known DDIs from the PDF monograph
Retrieve detailed NPRA license records — Re-query NPRA to populate individual product names, dosage forms, and approved indication text for the 42 registrations
Re-run TxGNN prediction pipeline — After data gaps are resolved, re-execute run_kg_prediction.py and collect the top-ranked disease candidates
Re-generate Evidence Pack — A new v5 pack with complete inputs will enable a full L1–L5 evidence assessment and Go/Proceed with Guardrails recommendation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.